{"entity":{"id":"vivace-therapeutics","kind":"company","name":"Vivace Therapeutics","aka":["Vivace Therapeutics, Inc.","Vivace Therapeutics, Inc"],"tldr":"A US company developing VT3989, a pill that blocks the Hippo pathway signal some tumours depend on. It is being tested mainly in mesothelioma, a cancer of the lining of the lungs and abdomen, now moving to a Phase 3 trial.","summary":"Vivace Therapeutics develops small molecules targeting the Hippo pathway. Its lead candidate, VT3989, inhibits autopalmitoylation of TEAD proteins. In its March 2025 release the company said VT3989 had been given to more than 150 patients in an open-label Phase 1 study in refractory metastatic solid tumours (NCT04665206, now Phase 1/2, including mesothelioma and NSCLC cohorts), with notable findings in mesothelioma after chemotherapy and immunotherapy. A Phase 3 trial of VT3989 in advanced epithelioid mesothelioma, with gemcitabine and vinorelbine as comparators, is registered as not yet recruiting with an estimated start in December 2026 (NCT07824986). The company closed a $35 million Series D led by RA Capital Management, with existing investors Canaan Partners and Cenova Capital, and said it had raised $105 million to date.","asOf":"2026-11-04","links":[{"label":"Series D press release, 12 March 2025","url":"https://www.biospace.com/press-releases/vivace-therapeutics-raises-35-million-in-series-d-financing-to-support-clinical-development-of-first-in-class-cancer-drug-targeting-the-hippo-pathway"},{"label":"ClinicalTrials.gov NCT04665206","url":"https://clinicaltrials.gov/study/NCT04665206"},{"label":"ClinicalTrials.gov NCT07824986","url":"https://clinicaltrials.gov/study/NCT07824986"},{"label":"RA Capital portfolio entry","url":"https://www.racap.com/portfolio/vivace-therapeutics"}],"tags":[],"related":[],"cancers":["mesothelioma","pleural-mesothelioma"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["vt3989"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04665206"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company website returned 403 to a scripted request and was not read; the facts here come from the company's March 2025 press release (PR Newswire, read on BioSpace) and ClinicalTrials.gov. The 'website' field comes from the press release and the RA Capital page.","Founding year not stated in the sources read.","TEAD has no target id in OnCo, so targets are left empty.","NCT07824986 (Phase 3, mesothelioma) was confirmed through the ClinicalTrials.gov v2 API; it is not yet a trial record in OnCo."],"hq":"San Mateo, CA","country":"US","companyType":"biotech","website":"https://www.vivacetherapeutics.com/","stage":"startup","investors":["ra-capital"],"funding":[{"round":"Series D","year":2025,"amountUsd":35000000,"source":"https://www.biospace.com/press-releases/vivace-therapeutics-raises-35-million-in-series-d-financing-to-support-clinical-development-of-first-in-class-cancer-drug-targeting-the-hippo-pathway","note":"Led by RA Capital Management, with existing investors Canaan Partners and Cenova Capital; Jake Simson of RA Capital joined the board."}]},"route":"/companies/vivace-therapeutics/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"vt3989","kind":"drug","name":"VT3989","route":"/drugs/vt3989/"}],"trial":[{"id":"nct07824986","kind":"trial","name":"A Phase 3 Trial in Advanced Epithelioid Mesothelioma","route":"/trials/nct07824986/"},{"id":"nct04665206","kind":"trial","name":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","route":"/trials/nct04665206/"}],"company":[{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}]}}